Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube

Psychedelic microdosing — the practice of taking repeated, very small doses of classic psychedelics such as LSD or psilocybin — has become highly visible in popular media and online communities but remains under‑researched. Andersson and Kjellgren note that aside from a small number of experimental studies (including one double‑blind, placebo‑controlled microdosing trial and several uncontrolled or self‑report investigations), most evidence comes from surveys and internet forums. Social media platforms, and YouTube in particular, have played a substantial role in spreading user reports, dosing strategies, and peer advice, creating a rich but methodologically challenging source of naturalistic data. This study set out to improve understanding of how psychedelic microdosing is presented and discussed on YouTube and to develop a practical method for using YouTube as a qualitative data source. The investigators aimed to characterise motives, reported effects, dosing approaches, and the social interactions that surround the practice, analysing first‑hand self‑reports in videos together with their comment threads using an inductive thematic approach.

The study used a qualitative, naturalistic design based on publicly available YouTube content. On 19 September 2018 the authors ran a keyword search for "microdosing psychedelics" using Webometric Analyst to generate an initial set of videos. From 84 hits they manually screened and excluded irrelevant items, duplicates, and non‑English uploads, yielding 75 videos for further review. From these the team selected 32 videos that contained explicit first‑hand accounts (self‑rapports) of psychedelic microdosing for inclusion in the final dataset. The selected videos, their auto‑generated transcripts and subsequent comments were downloaded using browser tools (Ncapture) and auto‑transcripts were manually revised while re‑watching the footage. Video metadata (views, likes, channel statistics) were collected via YouTube statistics and Webometric Analyst. All transcripts and comments were imported into NVivo11 for qualitative coding and analysis. The final dataset comprised self‑rapports from 34 individuals (24 male, 10 female) appearing in the 32 videos, plus statements from 198 anonymous commenters. The videos totalled approximately 15 hours, the transcripts contained roughly 142,769 words, and there were 4,507 comment entries. At data collection time the included videos had accumulated over 1.2 million views and were uploaded across 25 channels. Analysis followed an inductive thematic approach based on Braun and Clarke. Coding was semantic and conducted within a realist epistemology; the researchers excluded second‑hand reports and discussions of procurement or cultivation. After iterative reading and coding, 1,723 coded elements were grouped into 231 basic categories, which were then abstracted into eight overarching themes. Codes and theme development were independently checked and agreed upon by both authors.

The thematic analysis produced eight principal themes encapsulating motives, subjective effects, strategies, and community interactions around microdosing. Overall, reports were predominantly positive, with a notable emphasis on therapeutic uses alongside enhancement and self‑development motives. Microdosing motives, expectations and context: Users described motives as falling into self‑treatment (for mental or neurological conditions), self‑optimization (productivity, creativity, performance), or a mixture of both; a minority cited curiosity. Microdosing was often embedded in broader health and lifestyle practices (diet, exercise, meditation), and YouTube itself functioned as both an information source and a site for follow‑up advice and emotional support. Enhanced states and heightened senses: Many accounts described subtle but noticeable acute changes in perception and attention — for example, altered time perception, increased ‘‘presence,’’ clearer sensory acuity, reduced internal mental chatter, greater focus and flow. Users portrayed these state shifts as foundational to subsequent psychological and behavioural changes. Insights and transformation: Microdosers frequently reported increased self‑reflection, access to personal insights, and psycho‑spiritual change. Examples included heightened authenticity, processing of past trauma or ‘‘shadow’’ material, improved emotional regulation, greater empathy and improved relationships, and a felt reconnection to nature. Improved abilities and optimal performance: Reports of enhanced creativity, problem‑solving, productivity and professional performance were common, with examples drawn from software development, music, academic work and athletics. Some users quantified perceived gains anecdotally (for example, one user reporting about 20% better performance), while others described improved social presence and leadership. Relief and cure for health conditions: Numerous self‑reports claimed substantial improvements in a range of conditions. Depression — including treatment‑resistant cases — featured prominently and was uniformly reported as improved or resolved by those users. Additional claims included reductions in anxiety (though findings here were mixed), improvements in PTSD and bipolar symptoms, reductions in addictive behaviours (alcohol, nicotine, other drugs), benefits for ADHD/ASD social and cognitive functioning, relief from cluster headaches, and isolated reports of improvements in dyspraxia and regained bladder control after spinal cord injury. These are presented as user testimonies; the study did not verify clinical diagnoses or objective outcomes. Unwanted effects and lack of results: Adverse experiences were described but generally characterised as minor; no reports of serious harm emerged from the dataset. Common negative reports included inadvertent over‑dosing (producing noticeable intoxication), increased anxiety or panic in some users, gastrointestinal discomfort, restlessness or ‘‘jitters,’’ insomnia (more often with LSD) and occasional reduced performance in specific cognitive tasks. Long‑term harms were mentioned as a possible concern but not observed in self‑reports. Microdosing approaches, strategies and dosage: The community exchanged practical guidance on dosing, testing and administration. The Fadiman protocol (approximately 1/10th of a full dose every fourth day) was frequently referenced, but many users adapted dose and schedule to individual sensitivity. Strategies to improve safety included reagent testing, volumetric dosing for LSD, sensitive scales or powdered mushrooms, ‘‘loading’’ tolerance adjustments, and journalling or objective self‑tracking (e.g. heart‑rate variability) to monitor effects. Substances discussed were mainly LSD and psilocybin and their analogues (1P‑LSD, 4‑ACO‑DMT), with occasional mentions of others. General viewpoints on microdosing: Explanations for effects combined biochemical and psycho‑spiritual narratives, invoking neuroplasticity, serotonin activity, and metaphors such as a ‘‘spirit of the mushroom.’’ Microdosing was often compared favourably to prescription stimulants or SSRIs by users who emphasised intent, therapeutic work and perceived lower abuse potential. Illegality and stigma were frequent practical concerns.

Andersson and Kjellgren interpret their findings as evidence that YouTube is a rich source of naturalistic, in‑depth qualitative data about contemporary microdosing practices and peer interactions. The analysed self‑reports and comment threads portrayed microdosing as part of both therapeutic self‑treatment and enhancement-oriented self‑optimization, with many users combining microdosing with lifestyle changes and intentional practices. While the public narrative often highlights productivity gains, the dataset leaned more toward reports of therapeutic and psycho‑spiritual benefit, with depression singled out as a particularly prominent and uniformly positively described outcome. The authors emphasise several methodological and interpretive caveats. The uncontrolled, self‑selected nature of YouTube reports means dosage, substance identity and concomitant behaviours cannot be verified; the sample is unlikely to be representative in a statistical sense. Crucially, the study cannot disentangle pharmacological effects from placebo, expectation, lifestyle changes or other concurrent interventions. The investigators note that some early controlled low‑dose LSD data and mechanistic knowledge of psychedelics make the reported outcomes plausible in principle, but they do not claim causal proof. Practical observations from the dataset include a narrow and individually variable ‘‘window’’ between sub‑perceptual and functionally impairing doses, and the authors therefore question whether rigid dose‑range definitions of microdosing are useful. Intentionality emerged as an important contextual variable in users’ narratives; Andersson and colleagues recommend that future clinical research consider intentions and self‑adjustment behaviour when designing protocols. The discussion also highlights the social function of online communities in sharing harm‑minimisation strategies, experiential knowledge and emotional support. Finally, the authors present strengths and limits of their approach: a genuinely inductive, broad qualitative method and a more demographically dispersed sample than some specialised forums are strengths, while the impossibility of experimental control, potential reporting biases, and unknown generalisability are key limitations. They call for further, controlled research to examine efficacy, dose‑sensitivity and long‑term risks, and for future studies to include the variable of personal intentions.

Microdosing with classic psychedelics, principally LSD and psilocybin, was portrayed on YouTube primarily as a tool for therapeutic benefit and personal enhancement, with most self‑reports describing positive effects. Therapeutic effects for depression were especially prominent among user testimonies. Community interactions on the platform functioned to exchange dosing strategies, reduce risks and provide social support, and the role of explicit intentions was repeatedly identified as shaping outcomes. The authors conclude that while the trend and claimed benefits merit further attention, questions about long‑term risks and causal efficacy require more rigorous empirical evidence.